Introduction
Asthma manifests as a complex respiratory syndrome of airway hyperesponsiveness and inflammation. Airway smooth muscle (ASM) shortening evokes airway obstruction that clinically manifests as a significant decrease in peak airflow (Deshpande and Penn, 2006) .
Common therapeutic interventions include the use of glucocorticoids to curb airway inflammation and are often combined with a long-acting β -agonist. Other therapies include leukotriene and muscarinic receptor antagonists that inhibit the activation of G q -coupled receptors that mediate parasympathetic and hormonal signaling regulating bronchomotor tone (Bel, 2013) . GPCR antagonists have somewhat limited efficacy in patients as the activation of multiple G q -coupled receptors contribute to the pathology of the disease (Moulton and Fryer, 2011; Scadding and Scadding, 2010) . It is plausible that inhibiting G q activation at the receptor or the G protein level would be an advantageous asthma therapeutic as G q -mediated ASM shortening is a primary contributor to bronchotone (Borchers et al., 2003; Pelaia et al., 2008) .
P4pal-10 is a pepducin antagonist derived from intracellular loop 3 of protease-activated receptor 4 (PAR4) (Covic et al., 2002) . In the initial report, P4pal-10 demonstrated efficacy in preventing PAR4-mediated platelet activation ex vivo and exhibited anti-thrombotic activities in vivo. Interestingly, P4pal-10 inhibited both PAR1-and PAR4-mediated platelet aggregation and it was suggested this was due to disruption of the activity of PAR1/PAR4 heterodimers and loss of responsiveness from both receptor subtypes. Moreover, while Covic et al. reported that P4pal-
its unique properties to understand mechanisms and application of broad-based G q inhibition in the treatment of airway disease.
The relative therapeutic advantage of broad-based G q inhibition was also studied using a small molecule inhibitor of G q activation, FR900359 (also known as UBO-QIC). FR900359 is a cyclic depsipeptide isolated from the roots of Ardisia crenatasims that is nearly structurally identical to the well-studied G q inhibitor YM-254890 (Fujioka et al., 1988; Taniguchi et al., 2003 , Takasaki et al., 2004 Bernard et al., 2014) . Although not as well-characterized as YM-254890, FR900359 likely retains the same properties and mode of operation. Structural studies of a YM-254890/Gα q complex revealed that the compound interacts with the hinge region between the α -helical domain and GTPase domain of Gα q (Nishimura et al., 2010) . These contacts may inhibit the opening of the nucleotide binding pocket that is requisite for GDP/GTP exchange and subsequent G protein activation. Recent studies using FR900359 demonstrate efficacy in inhibiting G q -mediated signaling in human platelets with little effect on the activity of G s , G i or G 12/13 (Inamdar et al., 2015) . Further, the proposed vasorelaxant properties were confirmed in an ex vivo model of rat aortic relaxation (Zaima et al., 2013) . FR900359 has also been used as a molecular tool to dissect cellular signaling pathways that include the influence of Gβ5-RGS7 complex formation on G q -mediated calcium flux (Karpinsky-Semper et al., 2014) .
Here, we assessed the ability of FR900359 to inhibit G q -dependent airway smooth muscle growth and airway contraction.
Materials and Methods
Materials-P4pal-10 (palmitate-SGRRYGHALR-amide), scrambled P4pal-10 (P4pal-10 Scr, palmitate-YLHARGSRGR-amide) and PAR1-agonist peptide (PAR1-AP, SFLLRN) were
synthesized by an Fmoc solid-phase protocol and purified to >98% by C18 reverse-phase chromatography (Peptide2.0). FR900359 was acquired under the name of UBO-QIC from the Pharmazeutische Biologie at the Universität Bonn. Pertussis toxin from Bordetella pertussis, adenosine 5′-triphosphate disodium salt hydrate (99%), bradykinin (RPPGFSPFR) acetate salt (99%), forskolin from Coleus forskohlii (≥ 98%), (-)-isoproterenol hydrochloride (≥ 98%) and histamine (≥ 97%) were purchased from Sigma-Aldrich. Carbamylcholine chloride (carbachol, 99%) was purchased from Acros Organics. Purified recombinant human SDF-1α was obtained from ProSpec.
Cell Culture-HEK293 and HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum (FBS). Primary human airway smooth muscle cells were isolated from donors with no known chronic illness or medication use as previously described (Panettieri et al., 1989) . Passages 4 to 7 ASM cells were maintained in complete medium (Ham's F-12 medium supplemented with 10% FBS, 25 mM HEPES, pH 7.2, 1.7 mM CaCl 2 , 2 mM L-glutamine, 0.2 units/ml of penicillin, and 100 μ g/ml streptomycin). The use of human ASM cells does not constitute human subjects research as all donor tissue is harvested anonymously and de-identified. All cells were maintained at 37 °C in a humidified 5% CO 2 incubator. Cells were untransfected unless specifically noted.
Calcium Mobilization-Calcium mobilization was performed as previously described with slight modifications (Luo et al., 2008) . HEK293 cells or primary human ASM cells were grown to confluence in 15 cm dishes. Cells were treated with CellStripper (CellGro), washed and concentrated to 5x10 6 cells/mL in Hank's Balanced Salt Solution (HBSS, CellGro) with 0.025%
BSA. Fura2-AM (Life Technologies) dye was added to 2 μ M, gently rocked and incubated for 45 min at 37 °C. Cells were pelleted by centrifugation and the supernatant was replaced with 5 mL
7 of HBSS and incubated at room temperature for 15 min to allow Fura2-AM processing. Cells were pelleted by centrifugation, washed and resuspended at 30x10 6 cells/mL in ice-cold HBSS with 0.025% BSA. To measure calcium mobilization, 50,000 cells were incubated in HBSS without calcium and magnesium (Cellgro) with 0.025% BSA in the presence or absence of various concentrations of P4pal-10 for 1 min at 37 °C. Cells treated with FR900359 were incubated on ice for 10 min before addition to the assay cuvette and 1 min incubation at 37 °C before addition of agonists (final concentrations: 100 μ M PAR1-AP, 100 μ M carbachol, 100 nM bradykinin, 100 μ M histamine, 10 μ M ATP; concentrations that promoted maximal calcium mobilization were used). Fura2-AM fluorescence was monitored using excitation at 340 and 380
nm and emission at 510 nm over a time course (LS55; PerkinElmer). Percent responsiveness was calculated as the fraction of peak response of the inhibitor treated cells as compared to the response of the cognate ligand using cells not treated with inhibitor.
G s activation-HEK293 cells were plated in 24-well plates and grown to confluence in complete media. Before assaying, cells were treated with DMSO (0.5%), 100 nM FR900359, 10 μ M P4pal-10 or 10 μ M P4pal-10 Scr for 10 min at 37 °C. Cells were stimulated with 100 nM isoproterenol for 10 min in the presence of 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, SigmaAldrich). Cells were lysed by the addition of 80 μ L 0.1 M HCl followed by a 20 min incubation on an orbital shaker at room temperature. Lysates were cleared by centrifugation at 1,000 x g for 10 min. cAMP levels were measured using the Cayman Chemical Cyclic AMP EIA kit following the manufacturer's instructions. Responsiveness was calculated as a percent of isoproterenolpromoted cAMP produced as compared to the DMSO-treated cells.
G i activation-HEK293 cells were plated in 24-well plates and grown to confluence in complete media. Before assaying, cells were treated with DMSO (0.5%), 100 nM FR900359, 10
8 μ M P4pal-10 or 10 μ M P4pal-10 Scr for 10 min at 37 °C. In pertussis toxin treated samples, cells were preincubated overnight with 100 ng/ml pertussis toxin at 37 °C. Cells were treated for 1 min with agonist (50 nM SDF-1α for CXCR4 experiments; 100 μ M PAR1-AP for PAR1 experiments) before stimulation with 10 μ M forskolin for 10 min. cAMP production was measured as described above. Responsiveness was calculated as a percent of forskolin-promoted cAMP produced as compared to the DMSO-treated cells.
Gα q purification-Rat Gα q and Glutathione-S-Transferase (GST)-tagged Ric-8A were coexpressed from amplified, recombinant baculoviruses (2 ml and 8 ml, respectively) in 1L of High-Five (Invitrogen) insect cell suspension culture for 48 h. Insect cells were harvested and lysed in 20 mM HEPES, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol (DTT), 11 mM CHAPS, 1 µM GDP, and protease inhibitor mixtures, as described (Chan et al., 2011a) .
GST-Ric-8A:Gα q complexes were captured from the clarified lysates with glutathione Sepharose 4B (GE Healthcare). The column was washed and Gα q was eluted slowly at 22 ºC with 20 mM HEPES, pH 8.0, 50 mM MgCl 2 , 1 mM DTT, 11 mM CHAPs, 100 µM GDP, 10 mM NaF, 30
µM AlCl 3 , and protease inhibitor mixtures. The Gα q was loaded onto a 1 ml Hi-Trap Q column (GE Healthcare) that had been equilibrated with 20 mM HEPES, pH 8.0, 1 mM EDTA, 1 mM DTT, 11 mM CHAPS, and eluted with a linear gradient to 500 mM NaCl in the same buffer.
The Gα q Hi-Trap Q pool was concentrated using an Amicon Ultra-15 30,000 MWCO ultracentrifugal device and gel filtered over a Superdex 200 HR10/300 column in 20 mM HEPES, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 11 mM CHAPS, 1 µM GDP. The Gα q was evaluated for purity by Coomassie-stained SDS-PAGE and for activity using a Ric-8A-stimulated [ 35 S]-GTPγS binding assay (Chan et al., 2011b) .
Spontaneous GTPγS binding-Intrinsic Gα q GTPγS binding measurements were performed as described (Nishimura et al., 2010 hr at 30 °C. Cells were pelleted by centrifugation at 5000 x g for 15 min at 4 °C and resuspended in 10 mL of STE buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and 1 Complete protease inhibitor tablet (Roche)). 100 μ L of 1 M DTT and 1.4 mL of 10% Sarkosyl were added and mixed by inversion. The resuspension was sonicated for 1 min and centrifuged at 18,000 x g for 30 min at 4 °C. 4 mL of 10% Triton X-100 was added to the supernatant and the solubilized mixture was supplemented with STE buffer to 20 mL. 1 mL of Glutathione Sepharose beads, pre-equilibrated with Delbecco's phosphate buffered saline (DPBS), was added to the cleared lysate. GST-RBD loading occurred over a 1 hr incubation at room temperature with gentle
rocking. Glutathione Sepharose beads were pelleted and washed 3 times with 50 mL of DPBS.
Washed beads were suspended in DPBS, snap-frozen and stored at -80 °C.
HeLa cells were grown in 6-well plates to 60% confluence and transfected with FLAG-PAR1
for 48 hr prior to experiment using X-tremeGENE 9. Transfected HeLa cells were washed with DPBS and serum starved in DMEM for 4 hr at 37 °C. 10 min before stimulation, 10 μ M P4pal-10, 100 nM FR900359 or 0.5% DMSO was added to the appropriate wells. 
Preparation of precision cut lung slices-Human precision cut lung slices (PCLS) were prepared from donor lungs unsuitable for transplantation in accordance with the Institutional
Review Board at the University of Pennsylvania as previously described (Cooper and Panettieri, 2008; Cooper et al., 2011) . Briefly, whole human lungs from non-asthma donors with no known chronic illness or medication use were dissected and inflated using 2% (wt/vol) low melting point agarose. Once the agarose set, the lobe was sectioned, and cores of 8-mm diameter were made. The cores that contained a small airway by visual inspection were sliced at a thickness of 13 slices containing contiguous segments of the same airway were paired and served as controls and were incubated at 37°C in a humidified air-CO 2 (95-5%) incubator. Sections were placed in fresh media every 2-3 hr during the remainder of day 1 and all of day 2 to remove agarose and endogenous substances released that variably confound the production of inflammatory mediators and/or alter airway tone.
Precision cut lung slice bronchoconstriction measurements-To assess luminal area, lung slices were placed in a 12-well plate in media and held in place using a platinum weight with nylon attachments. The airway was located using a microscope (Nikon Eclipse; model no.
TE2000-U; magnification, ×40) connected to a live video feed (Evolution QEi; model no. 32-0074A-130 video recorder). Airway luminal area was measured using Image-Pro Plus software (version 6.0; Media Cybernetics) and represented in units of square micrometers (Cooper and Panettieri, 2008; Cooper et al., 2011) . After functional studies, the area of each airway at baseline and for each dose of agonist was calculated using Image-Pro Plus software.
Lung slices were pretreated with FR900359 (0.1 or 1 μM), P4pal-10 (20 μM) or P4pal-10 Scr (20 μM) for 30 min at 37°C. Slices were then bronchoconstricted to a dose response of carbachol or histamine (10 -8 -10 -4 M). Luminal area was measured and sigmoidal dose response curves generated from the data. Maximal bronchoconstriction (E max ), sensitivity of the airways to contractile agonist -log of the effective concentration to induce 50% bronchoconstriction (Log EC 50 ), and the integrated response to contractile agonist -area under the curve were calculated from the dose response curves generated and compared.
Magnetic twisting cytometry-Dynamic changes in cell stiffness were measured in isolated human ASM using forced motions of functionalized beads anchored to the cytoskeleton through cell surface integrin receptors, as described in detail previously (Fabry et al., 2001; This article has not been copyedited and formatted. The final version may differ from this version. Advanced BioMatrix, Inc.) at 500 ng/cm 2 , and maintained in serum-free media for 24 h at 37ºC in humidified air containing 5% CO 2 . These conditions have been optimized for seeding cultured cells on collagen matrix and for assessing their mechanical properties (Fabry et al., 2001; An et al., 2006; Deshpande et al., 2010) . For each individual cell, baseline stiffness was measured for the first 60 sec and after drug addition stiffness was measured continuously for the next 240 sec; drug-induced changes in cell stiffness approached a steady-state level by 240 sec.
Unless otherwise stated, ASM cells were pre-treated for 5 min with 3 μ M pepducin. The effects of inhibitors were normalized to respective steady-state drug effects (without inhibitors).
Results
P4pal-10 is an antagonist of multiple G q -coupled receptors. P4pal-10 is a ten amino acid pepducin derived from the third intracellular loop of PAR4 and was previously shown to inhibit G q -signaling from PAR4, PAR1 and the TXA 2 R (Covic et al., 2002; Stampfuss et al., 2003) . To assess whether P4pal-10 broadly inhibits G q signaling, we monitored agonist-promoted calcium mobilization from endogenous GPCRs in HEK293 cells and in primary human ASM cells.
P4pal-10 effectively inhibits responsiveness to a number of agonists including carbachol, bradykinin, histamine and ATP, with potencies that range from 0.24 μM (bradykinin) to 7.4 μM (ATP) (Fig. 1A & B) . To examine if P4pal-10 was specific for G q -coupled GPCRs, the ability to inhibit G protein activation from the β 2 AR (G s -coupled) and CXCR4 (G i -coupled) was also This article has not been copyedited and formatted. The final version may differ from this version. 15 assessed. P4pal-10 was unable to modulate cAMP production from the β 2 AR (Fig. 1C) or adenylyl cyclase inhibition from CXCR4 (Fig. 1D) . Thus, it appears that P4pal-10 operates through a specific subset of G q -coupled receptors and does not act as a broad antagonist for G protein-receptor coupling.
P4pal-10 inhibits cognate G protein coupling to PAR1 while FR900359 directly inhibits G q activation. It is plausible that P4pal-10 could operate by selectively inhibiting G q activation in a receptor-dependent manner or by directly inhibiting activation of G q . To dissect these potential mechanisms of action, the ability to modulate spontaneous nucleotide exchange was assessed using purified Gα q . P4pal-10 had little effect on the rate of nucleotide exchange of Gα q suggesting that it does not operate by directly restraining G q dynamics ( Fig. 2A) . We also evaluated the effects of the G q inhibitor FR900359 and, as expected, FR900359 effectively inhibits GTPγS incorporation and corroborates the similarities with YM-254890.
PAR1 is a protease-activated receptor that, when stimulated by thrombin or an exogenous peptide ligand, couples to G q , G i and G 12/13 (Fig. 2B ) (Gilchrist et al., 2001) . As PAR1 couples to multiple G proteins and is sensitive to P4pal-10 (Fig. 1A) , it serves as a good model to further dissect the mechanism of P4pal-10 inhibition. In a receptor-dependent model, P4pal-10 might operate by selectively inhibiting G q coupling to PAR1 or by inhibiting cognate G q , G i and G 12/13 coupling to PAR1. To study the ability of P4pal-10 and FR900359 in isolation, the cognate signaling from each G protein subtype was assessed in cells. Both FR900359 and P4pal-10 can inhibit PAR1-agonist peptide (PAR1-AP) stimulated calcium mobilization, an event typically associated with G q activation (Fig. 2C) . Activation of G i decreases cAMP production due to inhibition of adenylyl cyclase activity (Bokoch et al., 1984) . PAR1-mediated G i coupling resulted in an ~40% decrease in forskolin-stimulated cAMP production. Cells pretreated with This article has not been copyedited and formatted. The final version may differ from this version. P4pal-10 were unable to modulate forskolin-stimulated cAMP production similarly to cells pretreated with pertussis toxin, a well-characterized inhibitor of G i activation (Fig. 2D) . The scrambled control pepducin had no effect on adenylyl cyclase inhibition while FR900359 also did not alter G i function, as it is a G q specific inhibitor (Fig. 2D) . PAR1 also couples to G 12/13 activity that can be monitored through the detection of activated RhoA ( 17 mediated G 12/13 inactivation) (Kong et al., 2006) . As G q plays a central role in this phenomenon, it is plausible that the inhibition of G q activation could decouple the synergistic growth response from typical responsiveness to receptor tyrosine kinase-dependent growth factors. To examine this, primary human ASM cells were growth-arrested and exposed to thrombin (1 U/mL), epidermal growth factor (EGF, 10 nM) or co-treatment (thrombin + EGF) in the presence or absence of P4pal-10 or FR900359. As expected, ASM cells showed modest growth when treated with thrombin; more pronounced growth in the presence of EGF; and synergistic growth when co-treated with thrombin and EGF (Fig. 3A) . FR900359 effectively inhibited the synergistic growth effect of thrombin + EGF treatment to levels comparable to EGF stimulation alone while cellular responsiveness to EGF was unaltered. P4pal-10 mirrored the pharmacological profile of FR900359 while P4pal-10 Scr had no effect on ASM growth (Fig. 3A) .
The activation of G q -coupled GPCRs leads to the activation of myriad intracellular signaling pathways that can contribute to cell growth. Interestingly, the synergy between G q -coupled receptor agonists operates primarily through Gβγ-dependent activation of Akt and downstream targets of Akt, particularly P70 S6 kinase (P70S6K) (Ediger and Toews, 2000; Krymskaya et al., 2000; Kong et al., 2006) . Inhibition of src, Rho and Rho kinase along with knockdown of β -arrestin suggests no role for these signaling pathways in synergistic ASM growth (Kong et al., 2006) . Gβγ promotes AKT activation by direct phosphatidylinositol-3-kinase (PI3K) recruitment, phosphoinositide-dependent kinase-1 (PDK1) activation, and AKT-T308 phosphorylation by PDK1 (Billington et al., 2005) . As for Gα q , the signaling cascade that activates AKT is not as well established in ASM. Similar to the phenotypic growth assays, growth-arrested primary human ASM cells were treated, in the presence or absence of P4pal-10 or FR900359, with thrombin (1 U/mL), EGF (10 nM) or thrombin and EGF. Using an AKT This article has not been copyedited and formatted. The final version may differ from this version. 3B ). Both FR900359 and P4pal-10 effectively inhibited synergistic responsiveness to levels comparable to cells treated with EGF alone. P4pal-10 Scr had little effect on agonist-promoted AKT phosphorylation (Fig. 3B) .
FR900359, but not P4pal-10, can interdict bronchoconstriction in human precision cut lung slices. Airway hyperresponsiveness and amplified ASM shortening define the asthmatic diathesis. ASM contraction is mediated through myosin light chain phosphorylation downstream of G q activation (Hakonarson and Grunstein, 1998) . Parasympathetic stimulation of airway contraction is primarily mediated through the M 3 muscarinic acetylcholine receptor (Canning and Fischer, 2001 ). However, it is known that activation of multiple G q -coupled GPCRs, including PARs and histamine receptors, can feed into the dynamics of airway contraction (Deshpande and Penn, 2006) . Current therapeutic approaches may include the use of muscarinic or leukotriene receptor antagonists to attenuate the relative contribution of these receptors to the contractile state (Bel, 2013) . Conceivably, due to the heterologous nature of the signaling inputs that regulate airway contraction, a molecule that inhibits multiple G q -coupled receptors, such as P4pal-10, or a molecule that directly inhibits G q activation, such as FR900359, may offer unique therapeutic benefits.
P4pal-10 and FR900359 inhibited the activation of G q -dependent processes such as calcium mobilization or synergistic ASM growth. However, these assays were performed with either suspended cells or ASM cells grown in monolayer. As ASM in situ is situated under a layer of epithelial cells in the airway, the therapeutic potential of P4pal-10 and FR900359 in the context of a bronchial tissue was studied using human precision cut lung slices. As an ex vivo model of while P4pal-10 Scr had little effect on the EC 50 ( Fig. 4E & F) .
While it is expected that P4pal-10 would have the properties to interdict carbachol and histamine-promoted airway contraction, we observed relatively weak inhibition of these processes as compared to FR900359 (Fig. 4C & E) . In the airway, the smooth muscle is situated under a layer of epithelial cells that P4pal-10 would have to bypass or transverse to access the ASM.
To more directly assess the ability of P4pal-10 to inhibit isolated ASM cell contraction, magnetic twisting cytometry was used to assay single cell contraction. P4pal-10 effectively inhibited carbachol and histamine-promoted single cell ASM contraction while having no effect on isoproterenol-promoted relaxation ( Fig. 4F-H) . Additionally, P4pal-10 Scr did not exhibit any significant effects on agonist-promoted single cell contraction or relaxation ( Fig. 4F-H) . As 
Discussion
Asthma, a complex airway syndrome, manifests as airway hyperresponsiveness and inflammation due to multiple environmental and signaling inputs resulting in the exclusion of the airway lumen. G q plays a central role in the pathophysiology of airway disease and mediates ASM contractility, airway remodeling and ASM cell growth (Deshpande and Penn, 2006) . To assess the effects of broadly inhibiting G q activation, we examined a receptor-dependent pepducin antagonist of G q -activation alongside a small-molecule, direct inhibitor of G q activation.
P4pal-10 is a pepducin antagonist derived from intracellular loop 3 of PAR4. In the initial report, P4pal-10 exhibited strong inhibition of PAR4-mediated platelet aggregation with an IC 50 of ~ 0.5-1 μM and, interestingly, was able to also modulate PAR1-mediated platelet aggregation (Covic et al., 2002) . P4pal-10 could also inhibit G q -signaling in response to TXA 2 R stimulation (Stampfuss et al., 2003) , although this effect was not observed by Covic et al (Covic et al., 2002) . By monitoring calcium mobilization in HEK293 and human ASM cells, P4pal-10 inhibited a number of G q -coupled receptors with IC 50 s ranging from 0.24-7.4 μM. As the efficacy of P4pal-10 varied greatly depending on the agonist specificity, it seems unlikely that P4pal-10 is directly sequestering G q and preventing receptor interaction. Indeed, P4pal-10 did not modulate nucleotide exchange using purified Gα q . An interesting property exhibited by P4pal-10 concerns the ability to interdict all G protein coupling to a single receptor. PAR1 can couple to G q , G i and G 12/13 , all of which can be inhibited by P4pal-10. It is unknown, at this time, if P4pal-10 operates by restricting conformational dynamics of its targeted receptors to stabilize an inactive state or if P4pal-10 prevents receptor interaction with a G protein.
As P4pal-10 appears to operate through the receptor, the mechanism in which P4pal-10 inhibits a diverse set of G q -coupled receptors remains elusive. It was previously believed that pepducins operate through the cognate receptor from which they were derived (O' Callaghan et al., 2012); however, some pepducins, including P4pal-10, exhibit efficacy across multiple receptor subtypes (Stampfuss et al., 2003 , Carr III et al., 2014 . While many of these receptors do not share significant sequence similarity, many of the P4pal-10 sensitive receptors share strong, sequential homology with the N-terminal-half of the P4pal-10 sequence (SGRRYG). Some receptors that were characterized as P4pal-10 insensitive, such as the β 2 AR, may share some sequence homology with P4pal-10 but these regions of similarity are either short and highly disjointed or found in receptor regions that are likely not playing a role in P4pal-10 function (extracellular loops and transmembrane domains). Further, P4pal-10 sensitive receptors exhibited sequence homology with P4pal-10 in the intracellular domains of the receptor along with some portions of transmembrane domains that border the intracellular surface. With this in mind, P4pal-10 may interrupt critical intra-receptor or receptor-G protein contacts that are necessary for agonist-promoted G protein activation. As each receptor has distinct differences in receptor sequence, the spectrum of P4pal-10 sensitivity (Fig. 1A & B) may be attributed to the degree of similarity between the receptor and P4pal-10 or the unknown P4pal-10 interaction site.
FR900359, also known as UBO-QIC, was first reported as a methanol-extracted natural compound isolated from Ardisia crenata sims that was proposed to inhibit in vitro platelet aggregation and decrease blood pressure in rats (Fujioka et al., 1988) . Similar to the well-studied YM-254890, FR900359 directly inhibited in vitro spontaneous nucleotide exchange using This article has not been copyedited and formatted. The final version may differ from this version. 
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purified Gα q which suggests that it is operating by constraining G q conformational dynamics.
Our studies confirmed the proposed specificity of the compound at concentrations ten-times higher than concentrations previously studied in vitro. FR900359 did not modulate G s , G i or G 12/13 signaling while strongly inhibiting G q activation (Inamdar et al, 2015) . As many GPCRs couple to multiple G proteins, the use of an inhibitor with defined specificity can effectively bias signaling from a GPCR. Most often studied is the ability of a GPCR agonist to promote a biased consequence of G q -promoted calcium mobilization (Hakonarson and Grunstein, 1998) . Although the mechanism of elevated G q -signaling remains incompletely understood, it is believed that increased parasympathetic activation of the airway along with a local increase in G q -coupled receptor agonists (e.g., thrombin, histamine, ATP) enhances contractile state of an asthmatic airway. It is suspected that both inputs contribute to the pathology as muscarinic antagonists only partially alleviate airway tension in patients (Bel, 2013) . Using ex vivo human precision cut lung
slices, direct inhibition of G q activation by FR900359 was able to significantly impact airway contraction. Thus, it is conceivable that the use of a G q specific inhibitor may be an advantageous approach to the complex nature of treating bronchoconstriction in the asthmatic airway.
G q also contributes to airway remodeling, including ASM growth, that physically occlude the lumen of the airway (Al-Muhsen, 2011) . ASM proliferation is exacerbated in the disease state due to multiple factors including the increased presence of G q -coupled receptor agonists such as histamine, acetylcholine, thromboxane, leukotriene D4, serotonin and ATP in the airway (Deshpande and Penn, 2006) . In vitro models of ASM growth have established a synergistic relationship between the growth effects of receptor tyrosine kinase ligands, such as EGF and platelet-derived growth factor, and concurrent exposure to G q -coupled receptor ligands that is mediated through the activation of Akt and P70S6K (Ediger and Toews, 2000; Krymskaya et al., 2000; Kong et al., 2006) . Both P4pal-10 and FR900359 inhibited synergistic ASM growth and synergistic AKT activation with similar efficacy. These compounds, through fundamentally different mechanisms, inhibit synergy without modulating cellular responsiveness to a RTK growth factor further corroborates the critical role G q plays in this phenomena and pathology. G q can also promote the release of inflammatory factors such as cytokines (Fujii et al., 1998; Fujii and Kawashima, 2000) . Considering the data monitoring ASM contractility and growth, it would be expected that both P4pal-10 and FR900359 may have a significant impact on the efficacy of this process.
To date, the in vivo efficacy of pepducins has been limited to treating diseases in which the target cell type is readily accessible. For example, PAR1-and PAR4-targeted pepducin antagonists were demonstrated to have significant efficacy in interdicting platelet thrombosis in mouse and non-human primate disease models (Covic et al., 2002; Zhang et al., 2012) . In nude
mice, P1pal-7 effectively inhibited epithelial-derived lung tumor formation comparably to the current therapeutic standard Bevacizumab (Cisowski et al., 2011) . A CXCR2 pepducin antagonist inhibited inflammation and spontaneous tumor development by inhibition of CXCR2-rich leukocyte association in an invasive intestinal adenocarcinoma murine model (Jamieson et al., 2012) . It should be noted that each of the targeted cell types, such as platelets and leukocytes, were primarily accessible to circulating pepducins. In a tissue, the target cell types will likely need to have a surface accessible to the bloodstream in order for pepducin delivery. As pepducins do not have a particular targeting mechanism, the hydrophobic N-terminal palmitoyl group will likely incorporate into any membrane that it comes in contact with. In a multilayered tissue, the outermost cell type, epithelial cells in the case of the airway, may act as a sink to capture much of the available pepducin. This hypothesis is corroborated by the phenomena observed while monitoring ASM signaling pathways and contraction in cell monolayer in comparison to airway contraction in an ex vivo, intact airway using precision cut lung slices.
P4pal-10 was unable to modulate airway contraction in the airway tissue but exhibited strong efficacy in inhibiting single cell contraction using isolated ASM cells. Additionally, P4pal-10 could inhibit G q -dependent signaling in cell suspension or monolayer. Plausibly, as the ASM is situated under an epithelial layer, P4pal-10 cannot adequately penetrate the tissue to reach the ASM. In contrast, FR900359 significantly inhibited agonist-promoted contraction in the precision cut lung slices. These observations are likely a commentary on the current therapeutic limitations of the use of pepducins to treat human disease. As previously demonstrated, pepducins can offer novel therapeutic approaches if the targeted cell type is not part of a multilayered tissue (i.e., platelets, leukocytes) or it is able to interact with bioavailable pepducin (i.e., lung epithelial tissue). Beyond therapeutic application, it is becoming increasingly clear that
pepducins, including P4pal-10, can provide unique pharmacological tools and profiles that are not currently ascertainable using orthosteric ligands.
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Figure Legends 32 data are represented by the mean ± SD from three independent experiments. ns-not significant, ***-p< 0.001 versus PAR1-AP-treated cells using a two-way unpaired t-test. by the mean ± SD of three independent experiments. ns-not significant, **-p< 0.01 versus vehicle-treated cells incubated with thrombin and EGF using a two-way unpaired t-test. (n=418) or P4pal-10 Scr (n=292) did not modulate isoproterenol-promoted single-cell relaxation as compared to "no inhibitor"/vehicle treatment (n=569). The data sets are normalized to "no inhibitor"/vehicle treatment. ns-not significant compared to vehicle-treated cells using a one-way ANOVA analysis.
